Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
OncXerna Therapeutics logo — Advancing a new paradigm of precision oncology with a RNA-ba...

OncXerna Therapeutics

Advancing a new paradigm of precision oncology with a RNA-based approach to match patients to novel, targeted treatments

Founded 2018 United States Waltham, United States 8 employees Venture round Total: $126.50M Biopharma, Biotechnology +3

General Information

Company Name OncXerna Therapeutics
Founded Year 2018
Location United States Waltham, United States
Founders / Decision Makers
Team member Team member
Employees 8
Industries Biopharma, Biotechnology, Health Care +2
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with OncXerna Therapeutics . To contact OncXerna Therapeutics , visit oncxerna.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does OncXerna Therapeutics compare?

A PDF of OncXerna Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting OncXerna Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About OncXerna Therapeutics

OncXerna Therapeutics is a clinical stage precision medicine oncology company founded in 2018, with a mission to advance a new paradigm of precision oncology using a RNA-based approach. The company's innovative precision medicine platform, Xerna™, leverages artificial intelligence technologies and RNA expression-based biomarkers to match a specific patient’s tumor with the most suitable drugs for treatment. OncXerna's lead product candidate, navicixizumab, is currently undergoing studies in ovarian cancer, triple-negative breast cancer, and colorectal cancer, while another product candidate, bavituximab, is in Phase 2 clinical trials. The company's focus on developing novel therapies to treat solid tumors demonstrates its commitment to bringing meaningful new treatments to patients as soon as possible. Its $30.00M Venture Round investment at 03 March 2022, led by Company K Partners and K2 HealthVentures, is a testament to the confidence investors have in the potential of OncXerna's innovative approach to precision oncology. With its deep expertise in clinical development, OncXerna aims to accelerate the development, approval, and commercialization of its drug product candidates, ultimately contributing to the advancement of precision medicine in oncology.

Business keywords: Precision Medicine, Oncology, RNA-based Biomarkers, Clinical-stage Therapies, Bispecific Antibodies, Drug Development, Cancer Treatment, Clinical Trials, Biopharmaceutical, Biomarker Platform, Precision Oncology, Tumor Microenvironments, Therapeutics, RNA Expression

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round $30.00M 2
Company K Partners K2 HealthVentures
Company K Partners, K2 HealthVentures
03 Mar 2022
Series B $80.00M 8
Korea Investment Partners KB Investments Nan Fung Life Sciences
Korea Investment Partners, KB Investments +6
10 Jun 2019
Seed Round $16.50M -
07 Jun 2018

OncXerna Therapeutics Alternatives & Competitors

View All Alternatives
OncXerna Therapeutics vs
Antharis Therapeutics, Inc.
Antharis Therapeutics, Inc. United States

Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting-edge trea...

18 employees
Biopharma, Biotechnology
OncXerna Therapeutics vs
Lisata Therapeutics, Inc.
Lisata Therapeutics, Inc. United States

Targeted Therapy Delivered

Acquired
39 employees
Biotechnology, Health and Wellness
OncXerna Therapeutics vs
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. United States

Delivering a cancer-free future

Post-IPO Equity
11 employees
Biotechnology, Health Care
Also compare with: OncXerna Therapeutics vs Acrivon Therapeutics, Inc. Acrivon Therapeutics, Inc. View all alternatives

FAQ About OncXerna Therapeutics

Advancing a new paradigm of precision oncology with a RNA-based approach to match patients to novel, targeted treatments
OncXerna Therapeutics was founded in 2018.
OncXerna Therapeutics is headquartered in Waltham, United States.
OncXerna Therapeutics operates in Biopharma, Biotechnology, Health Care, Medical Devices and Pharmaceutical. Its work centres on Precision Medicine, Oncology, RNA-based Biomarkers and Clinical-stage Therapies.
OncXerna Therapeutics has approximately 8 employees.
OncXerna Therapeutics has completed 3 funding rounds, raising a total of $126.50M. The latest funding stage is Venture round.
Top alternatives and competitors to OncXerna Therapeutics include Antharis Therapeutics, Inc., Lisata Therapeutics, Inc., TransCode Therapeutics, Inc., Anchiano Therapeutics, F-star Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
OncXerna Therapeutics and Antharis Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for OncXerna Therapeutics , https://bouncewatch.com/company/oncxerna-therapeutics, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout